CGRP Monoclonal Antibody Treatment for Medication Overuse Headache
Author Information
Author(s): Tanei Takafumi, Fuse Yutaro, Maesawa Satoshi, Nishimura Yusuke, Ishizaki Tomotaka, Nagashima Yoshitaka, Mutoh Manabu, Ito Yoshiki, Hashida Miki, Suzuki Takahiro, Yamamoto Syun, Wakabayashi Toshihiko, Saito Ryuta
Primary Institution: Nagoya University Graduate School of Medicine
Hypothesis
The study aims to evaluate the real-world clinical results of CGRP monoclonal antibody treatment for migraine with medication overuse headache without abrupt drug discontinuation and no hospitalization.
Conclusion
CGRP monoclonal antibody treatment significantly reduced headache frequency and acute medication use in patients with medication overuse headache without the need for abrupt drug discontinuation or hospitalization.
Supporting Evidence
- Monthly headache days decreased from 30.0 to 9.5 days after treatment.
- Monthly migraine days decreased from 10.0 to 1.5 days after treatment.
- Monthly acute medication use days decreased from 28.0 to 8.0 days after treatment.
- 75.0% of patients had a good response in reducing headache days.
- 85.7% of patients had a good response in reducing migraine days.
- 78.6% of patients effectively reduced their acute medication use.
Takeaway
This study shows that a special treatment can help people with headaches feel better without having to stop their usual medicine suddenly.
Methodology
Data were collected from patients before and after receiving CGRP monoclonal antibody injections, comparing headache days, medication use, and quality of life scores.
Potential Biases
Selection bias may exist as treatment was not randomly assigned.
Limitations
The study is retrospective, single-center, and lacks a control group for comparison.
Participant Demographics
{"mean_age":40.9,"female_percentage":87.9,"history_of_psychiatric_disorders_percentage":18.2,"migraine_with_aura_percentage":51.5}
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website